ViroPharma Inc. (VPHM) announced Tuesday morning that the FDA denied the citizen petition filed by ViroPharma on March 17, 2006, related to the FDA's proposed in vitro method for determining bioequivalence of abbreviated new drug applications referencing Vancocin Capsules. The FDA also approved three generic versions of the drug.
ViroPharma gapped open dramatically lower Tuesday, but was range-bound throughout the session. The stock finished down by 6.17 at $22.44 on the highest volume of the year. ViroPharma sank to over a 4-month low and fell below its 200-day moving average.
by RTT Staff Writer
For comments and feedback: email@example.com